On August 11, 2026, AstraZeneca PLC AZN faced significant market reactions following news of a potential $400 billion merger with Bristol-Myers Squibb (BMY). The proposed deal, which would create the largest pharmaceutical company globally by revenue, has raised concerns among investors.
- AstraZeneca currently offers a dividend yield of 1.97%, with a payout ratio that supports its sustainability, especially given the company's GF Valueâ„¢ of $181.00, indicating it is 10.5% undervalued.
- The GF Scoreâ„¢ for AstraZeneca stands at 85/100, reflecting strong fundamentals and growth potential.
- Insider activity shows no recent buying, with insiders selling $2.2 million worth of shares in the last three months, which may signal caution among company executives.
What's Behind the News?
The recent discussions between AstraZeneca's CEO Pascal Soriot and Bristol-Myers Squibb's CEO Giovanni Caforio have sparked significant interest in the pharmaceutical sector. Initially, Soriot had assured investors that achieving an ambitious $80 billion revenue target by 2030 would not necessitate large-scale acquisitions. However, the pursuit of this merger indicates a strategic pivot towards consolidating market power and expanding revenue streams, particularly in the U.S. market.
AstraZeneca, with a market capitalization of approximately $264 billion, operates primarily in the healthcare sector, focusing on drug manufacturing across various therapeutic areas, including oncology, cardiovascular, and rare diseases. The company has been actively enhancing its portfolio through strategic acquisitions, such as the $39 billion purchase of Alexion, which has positioned it for significant revenue growth.
Is AZN's Dividend Safe and Attractive?
AstraZeneca's current dividend yield of 1.97% reflects its commitment to returning value to shareholders, while the payout ratio suggests that the dividend is sustainable. The company has a history of dividend growth, which is an essential factor for income-focused investors. Given the company's robust financial position and the GF Valueâ„¢ assessment of $181.00, AstraZeneca appears to be trading at a 10.5% discount to its intrinsic value, making its dividend not only attractive but also potentially secure in the long term. For more details, visit the GF Valueâ„¢ page.
What Does AZN's GF Scoreâ„¢ Tell Us?
The GF Scoreâ„¢ evaluates a company's financial strength, profitability, growth potential, valuation, and momentum, providing a comprehensive overview of its investment quality. AstraZeneca's GF Scoreâ„¢ of 85 indicates strong fundamentals, with notable strengths in profitability and growth, ranked 8/10 and 9/10, respectively. However, its momentum rank of 3/10 suggests some volatility in stock performance.
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 85 |
| Financial Strength | 6/10 |
| Profitability | 8/10 |
| Growth | 9/10 |
| Valuation | 10/10 |
| Momentum | 3/10 |
Overall, AstraZeneca exhibits strong profitability and growth potential, although the lower momentum rank indicates that investors should be cautious about short-term fluctuations. For further insights, visit the AZN stock page.
What Are Gurus and Insiders Doing with AZN?
AstraZeneca is currently held by 11 gurus, with 9 adding to their positions and 2 trimming their holdings in recent quarters. This indicates a generally positive sentiment among institutional investors. However, insider activity has shown a net selling trend, with no recent insider buying and $2.2 million worth of shares sold, which could reflect caution regarding the company's future direction amidst merger discussions.
What This Means for Investors
In summary, AstraZeneca's strategic moves, including the pursuit of a significant merger, highlight its ambition to enhance revenue and market presence. The company's solid dividend yield, coupled with its undervaluation according to GF Valueâ„¢, suggests that it remains an attractive option for investors focused on both growth and income. For a deeper dive into AstraZeneca's financials, visit the AZN stock page.
Frequently Asked Questions
What is AZN's GF Scoreâ„¢?
AstraZeneca's GF Scoreâ„¢ is 85, indicating strong financial health and growth potential.
Is AZN's dividend safe?
With a yield of 1.97% and a sustainable payout ratio, AstraZeneca's dividend appears to be safe and attractive for investors.
What is AZN's P/E ratio compared to historical?
AstraZeneca's current P/E ratio is 23.99, which is significantly lower than its 5-year median P/E of 33.72, suggesting that the stock may be undervalued.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
